FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC

News
Article

The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with niraparib/abiraterone acetate dual action tablets in those with metastatic castration-resistant prostate cancer harboring a BRCA mutation.

FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC | Image Credit: © Dr_Microbe - stock.adobe.com.

The FDA previously approved niraparib plus abiraterone acetate and prednisone for patients with BRCA-positive metastatic CRPC in August 2023.

The FDA has approved the FoundationOne CDx as a companion diagnostic for identifying patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (CRPC) who may benefit from treatment with niraparib and abiraterone dual action tablets (Akeega), according to a press release from Foundation Medicine Inc.1

“With such a rapidly evolving therapeutic landscape in prostate cancer, high-quality companion diagnostics are important tools to support oncologists in the development of personalized treatment plans for each unique patient,” Mia Levy, MD, PhD, chief medical officer at Foundation Medicine, said in the press release. “This companion diagnostic specifically will help enable broader access to an important new therapy option in [BRCA1/2-mutated metastatic] CRPC.”

The FDA previously approved niraparib plus abiraterone acetate and prednisone for patients with BRCA-positive metastatic CRPC in August 2023.2 Supporting data for this approval came from the phase 3 MAGNITUDE trial (NCT03748641), in which investigators reported a 47% reduction in the risk of radiographic progression-free survival (rPFS) in the niraparib arm compared with placebo (HR, 0.53; P = .001). With a median follow-up of 24.8 months, the median rPFS by independent central review in the experimental and placebo arms, respectively, was 19.5 months vs 10.9 months (HR, 0.55; 95% CI, 0.39-0.78).

“We prospectively designed the MAGNITUDE study to identify the subset of patients most likely to benefit from targeted treatment with [niraparib and abiraterone acetate] and to help us understand how we can potentially achieve better health outcomes for patients,” principal investigator Kim Chi, MD, a medical oncologist at BC Cancer – Vancouver, said in a press release at the time of the agent’s FDA approval.2

The FoundationOne CDx, a next-generation sequencing device, is designed to detect insertion and deletion alterations, as well as substitutions across 324 genes, helping to identify patients who may be eligible to receive targeted therapies based on approved therapeutic product labelling.

According to the press release, the assay is intended exclusively for prescription use. Additionally, testing with the FoundationOne CDx does not guarantee that a patient will be matched to a treatment, and a negative test result does not negate the potential presence of an alteration.

The FDA approved the FoundationOne Liquid CDx assay in August 2020, which included an indication for rucaparib (Rubraca) as a treatment for patients with BRCA-mutated metastatic CRPC.3 The FDA also approved the FoundationOne Liquid CDx as a companion diagnostic for identifying patients with metastatic CRPC harboring a BRCA1/2 and/or ATM alteration who may be eligible to receive treatment with olaparib (Lynparza) in November 2020.4

References

  1. U.S. Food and Drug Administration (FDA) approves FoundationOne®CDx as a companion diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate dual action tablet) for patients with BRCA-positive metastatic castration-resistant prostate cancer. News release. Foundation Medicine Inc. August 14, 2023. Accessed August 17, 2023. https://shorturl.at/OUWZ4
  2. U.S. FDA approves AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer. News release. Janssen Pharmaceutical Companies of Johnson & Johnson. August 11, 2023. Accessed August 17, 2023. https://bit.ly/3QBbT0d
  3. FDA approves Foundation Medicine's FoundationOne®Liquid CDx, a comprehensive pan-tumor liquid biopsy test with multiple companion diagnostic indications for patients with advanced cancer. News release. Foundation Medicine Inc. August 26, 2020. Accessed August 17, 2023. https://shorturl.at/BHOP0
  4. Foundation Medicine expands indication for FoundationOne®Liquid CDx to be used as a companion diagnostic for LYNPARZA®. News release. Foundation Medicine Inc. November 9, 2020. Accessed August 17, 2023. https://shorturl.at/EGLUZ
Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.

EU’s CHMP Recommends Enzalutamide Approval in Non-Metastatic HSPC

March 25th 2024
Article

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

BXCL701 Earns FDA FTD in Small Cell Neuroendocrine Prostate Cancer

February 12th 2024
Article

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC

January 28th 2024
Article

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.